Outlook Therapeutics Inc
About
Outlook Therapeutics Inc (NASDAQ:OTLK) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 23 2026
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
Apr 22 2026
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Apr 21 2026
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Apr 7 2026
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
Mar 25 2026
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering